Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Glaukos (GKOS)

Glaukos files November 2026 investor presentation; $340 million cash, no debt

Neutral Impact 2 of 5 other

Glaukos furnished a November 2026 investor presentation as Exhibit 99.1 under Item 7.01, which it intends to use in investor meetings and post on its website. The filing is informational and does not set out a new earnings result or guidance change; it includes 3Q 2026 gross margin of 88% and cash of $340 million with no debt as of 9/30/2026.

Key points

  • Presentation dated November 2026, furnished as Exhibit 99.1 and not deemed filed under the Exchange Act
  • 3Q 2026 gross margin of 88%, adjusted for certain accounting and other items per the appendix
  • Cash and equivalents of $340 million and no debt as of 9/30/2026
  • Epioxa, described as the first and only FDA-approved epithelium-on keratoconus treatment, commercially available since March 2026

The filing

CompanyGlaukos (GKOS)
Form8-K, current report
Filed with the SECNov 6, 2026, 7:00 AM ET
Accession number0001193125-26-450710

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.